NVOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (2 5月 2024 @ 23:02):

Stats
本日の出来高	2.67M
平均出来高	4.84M
時価総額	557.70B
EPS	$0 ( 2024-01-31 )
Last Dividend	$0.884 ( 2023-08-18 )
Next Dividend	$0 ( N/A )
P/E	47.26
ATR14	$0.436 (0.34%)

ボリューム相関

長: -0.57 (weak negative)

短: 0.97 (very strong)

Signal:(58.82) Expect same movement, but be aware

Novo Nordisk A/S 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Novo Nordisk A/S 相関 - 通貨/商品

0.45
( neutral )

-0.12
( neutral )

0.64
( weak )

-0.18
( neutral )

-0.88
( strong negative )

-0.13
( neutral )

Novo Nordisk A/S 財務諸表

Annual	2023
収益:	$232.26B
総利益:	$196.50B (84.60 %)
EPS:	$18.67

FY	2023
収益:	$232.26B
総利益:	$196.50B (84.60 %)
EPS:	$18.67

FY	2022
収益:	$176.95B
総利益:	$148.51B (83.92 %)
EPS:	$12.26

FY	2021
収益:	$140.80B
総利益:	$117.14B (83.20 %)
EPS:	$20.46

Financial Reports:

No articles found.

Novo Nordisk A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.584 (N/A)	$0 (N/A)	$1.189 (N/A)	$0 (N/A)	$0.884 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novo Nordisk A/S Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.78 - good (77.78%) | Divividend Growth Potential Score: 4.56 - Stable (8.80%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.000600	1982-04-23
Last Dividend	$0.884	2023-08-18
Next Dividend	$0	N/A
Payout Date	2023-08-29
Next Payout Date	N/A
# dividends	53	--
Total Paid Out	$15.84	--
Avg. Dividend % Per Year	2.26%	--
Score	4.29	--
Div. Sustainability Score	7.78
Div.Growth Potential Score	4.56
Div. Directional Score	6.17	--

Next Divdend (Est)
(2024-05-27)

$0.906 Estimate 6.52 %

Dividend Stability

0.26 Very Poor

Dividend Score

4.29

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1982	$0.000600	0.30%
1983	$0.00274	1.29%
1984	$0.00288	1.02%
1985	$0.00259	2.18%
1986	$0.00344	2.37%
1987	$0.00414	2.50%
1988	$0.00522	4.51%
1989	$0.00463	2.39%
1990	$0.00624	2.51%
1991	$0.00509	1.64%
1992	$0.00600	1.32%
1993	$0.00540	1.22%
1994	$0.0112	2.26%
1995	$0.00840	1.80%
1996	$0.0158	2.26%
1997	$0.0112	1.24%
1998	$0.0161	1.13%
1999	$0.0164	1.17%
2000	$0.0422	3.13%
2001	$0.0318	1.79%
2002	$0.0369	1.84%
2003	$0.0523	3.56%
2004	$0.0745	3.62%
2005	$0.0840	3.17%
2006	$0.0966	3.39%
2007	$0.122	2.93%
2008	$0.177	2.77%
2009	$0.207	3.92%
2010	$0.281	4.28%
2011	$0.364	3.27%
2012	$0.499	4.26%
2013	$0.637	3.84%
2014	$0.830	4.52%
2015	$0.760	3.58%
2016	$1.411	4.92%
2017	$1.137	6.33%
2018	$1.137	4.20%
2019	$1.238	5.29%
2020	$1.301	4.46%
2021	$1.506	4.22%
2022	$1.620	2.98%
2023	$2.07	3.03%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.360	1.500	2.79	4.19	[0 - 0.5]
returnOnAssetsTTM	0.266	1.200	1.130	1.356	[0 - 0.3]
returnOnEquityTTM	0.905	1.500	1.056	1.585	[0.1 - 1]
payoutRatioTTM	0.380	-1.000	6.20	-6.20	[0 - 1]
currentRatioTTM	0.823	0.800	-0.884	-0.708	[1 - 3]
quickRatioTTM	0.622	0.800	-1.048	-0.839	[0.8 - 2.5]
cashRatioTTM	0.0848	1.500	-0.640	-0.960	[0.2 - 2]
debtRatioTTM	0.0859	-1.500	8.57	-10.00	[0 - 0.6]
interestCoverageTTM	69.78	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
freeCashFlowPerShareTTM	15.68	2.00	2.16	4.32	[0 - 20]
debtEquityRatioTTM	0.253	-1.500	8.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.846	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.442	1.000	3.17	3.17	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.739	0.800	8.41	6.73	[0.5 - 2]
Total Score				7.78

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	47.98	1.000	5.26	0	[1 - 100]
returnOnEquityTTM	0.905	2.50	4.25	1.585	[0.1 - 1.5]
freeCashFlowPerShareTTM	15.68	2.00	4.77	4.32	[0 - 30]
dividendYielPercentageTTM	0.113	1.500	7.17	0	[0 - 0.4]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
payoutRatioTTM	0.380	1.500	6.20	-6.20	[0 - 1]
pegRatioTTM	0.198	1.500	-2.01	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.469	1.000	0.777	0	[0.1 - 0.5]
Total Score				4.56

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

リアルタイムの更新： Novo Nordisk A/S [NVO]

Upcoming Earnings Alert

Novo Nordisk A/S Dividend Information - Dividend Knight

Dividend Commentary

Top 10 dividend Companies for NYSE

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)